Skip to main content

Advertisement

SpringerLink
Log in

Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL

  • Lymphoma (JW Sweetenham, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Approximately 10 % of cases of diffuse large B cell lymphoma (DLBCL) harbor a MYC rearrangement and this has been associated with an inferior outcome following standard therapy across many different studies. Double-hit and triple-hit lymphomas harbor concurrent rearrangements of MYC and BCL2 and/or BCL6 and are also associated with a very aggressive course and poor clinical outcome. It is unclear and there is lack of consensus on how these diseases should be approached therapeutically. They are characterized typically by high tumor proliferation and likely require Burkitt lymphoma-type strategies and several retrospective studies suggest that more intensive approaches than rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) may be beneficial. One challenge in this respect is that most patients with these diseases are older than 60 years and generally have poor tolerability of regimens typically used in Burkitt lymphoma. Dose-adjusted EPOCH-R is an alternative effective immunochemotherapy platform for DLBCL and is effective in Burkitt lymphoma, and retrospective studies suggest that it is effective and feasible in patients with DLBCL that harbors a MYC rearrangement with or without a BCL-2 translocation (double-hit). A multicenter study of this approach in MYC-rearranged DLBCL is ongoing and preliminary results are very encouraging. There is a lack of consensus on the role of consolidation stem cell transplantation in patients who achieve a good response to initial therapy but at this point in time, no (retrospective) studies have demonstrated any benefit. These diseases are also associated with a high rate of CNS involvement and progression and checking for cerebrospinal fluid by cytology and flow cytometry at initial diagnosis should be considered. In summary, based on retrospective data and preliminary prospective data (as more mature data is awaited), while Burkitt-type regimens may be feasible in young patients, DA-EPOCH-R is a reasonable approach for patients with these diseases, particularly for those over the age of 60 years. CNS prophylaxis is a reasonable consideration (depending on clinical characteristics) given that the rate of CNS progression is high. Many exciting new small molecule inhibitors such as BCL-2 and MYC inhibitors are in development and are exciting for these diseases and attempts are underway to combine them with effective immunochemotherapy platforms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.

    Article  CAS  PubMed  Google Scholar 

  3. Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, et al. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. Blood. 2015;125(6):959–66.

    Article  CAS  PubMed  Google Scholar 

  4. Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–56. This is a recently published retrospective study from the British Columbia group that looked at the outcome of a large group of DLBCL patients treated with R-CHOP. Outcome was looked at with respect to cell of origin (lymph 2CX assay) as well as BCL2 and MYC expression. Interestingly, the significance of high MYC and BCL2 expression was looked at within different molecular subtypes of DLBCL.

  5. Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, et al. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 2015;125(7):1137–45.

    Article  CAS  PubMed  Google Scholar 

  6. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–23.

    Article  CAS  PubMed  Google Scholar 

  7. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Medicine. 2015 Jul 20. PubMed

  10. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2015;33(3):251–7.

    Article  CAS  PubMed  Google Scholar 

  11. Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15(7):730–7.

    Article  CAS  PubMed  Google Scholar 

  12. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–31.

    Article  CAS  PubMed  Google Scholar 

  13. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Dunleavy K. Double-hit lymphomas: current paradigms and novel treatment approaches. Hematol Educ Prog Am Soc Hematol. 2014;2014(1):107–12.

  15. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360–5.

    Article  CAS  PubMed  Google Scholar 

  16. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7.

    Article  CAS  PubMed  Google Scholar 

  18. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–63.

    Article  CAS  PubMed  Google Scholar 

  19. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program. Blood. 2013;121(20):4021–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Wang XJ, Medeiros LJ, Lin P, Yin CC, Hu S, Thompson MA, et al. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. Am J Surg Pathol. 2015;39(9):1250–8.

    Article  PubMed  Google Scholar 

  21. Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res. 2011;17(24):7785–95.

    Article  CAS  PubMed  Google Scholar 

  22. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German high-grade Non-Hodgkin's lymphoma study group (DSHNHL). Leukemia. 2008;22(12):2226–9.

    Article  CAS  PubMed  Google Scholar 

  23. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–7.

    Article  CAS  PubMed  Google Scholar 

  24. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44(12):1316–20.

    Article  CAS  PubMed  Google Scholar 

  26. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Smith SD, Chen A, Spurgeon S, Okada C, Fan G, Dunlap J, et al. Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors. Ther Adv Hematol. 2013;4(6):349–53.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, et al. Approach to therapy of diffuse large B-cell lymphoma in the elderly: the international society of geriatric oncology (SIOG) expert position commentary. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015;26(6):1058–68.

    Article  CAS  Google Scholar 

  29. Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist. 2014;19(12):1249–57.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Dunleavy K, Pittaluga S, Wayne A, Shovlin M, Johnson J, Little R, et al. MYC + aggressive B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol 2011 22 (Suppl 4) Abstract 71. 2011.

  31. Dunleavy K, Fanale M, LaCasce A, Noy A. Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. Proc Am Soc Hem Meeting. 2014

  32. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–26.

    Article  CAS  PubMed  Google Scholar 

  33. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Pedersen MO, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92(1):42–8.

    Article  CAS  PubMed  Google Scholar 

  35. Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014;165(3):382–91.

    Article  CAS  PubMed  Google Scholar 

  36. Dunleavy K, Pittaluga S, Shovlin M, Pack S, Steinberg S, Lai C. Concurrent expression of MYC/BCL2 protein in newly diagnosed DLBCL is not associated with an inferior survival following EPOCH-R therapy. Blood (ASH AnnuMeet Abstr). 2013;122(29):3029.

    Google Scholar 

  37. Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t (14;18) (q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145–56.

    Article  CAS  PubMed  Google Scholar 

  39. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61. This multi-center retrospective study looks at the outcome of over 300 patients with ‘double-hit’ lymphoma following several different therapeutic approaches and assesses the impact on prognosis of various factors such as induction regimen used and consolidation stem cell transplantation.

    Article  CAS  PubMed  Google Scholar 

  40. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891–901. This study from MD Anderson looks at the outcome of over 100 patients with ‘double-hit’ lymphoma (retrospectively) and assesses the impact of treatment and various other factors on prognosis.

    Article  CAS  PubMed  Google Scholar 

  41. Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–14.

    Article  PubMed  Google Scholar 

  42. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollert-Wulf B, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(30):12420–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. 2013 Jun 24. PubMed Epub 2013/06/25. Eng.

  48. Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Jul 9. PubMed Epub 2014/07/11. Eng.

  49. Bhadury J, Nilsson LM, Veppil Muralidharan S, Green LC, Li Z, Gesner EM, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A. 2014;111(26):E2721–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Sheth A, Escobar-Alvarez S, Gardner J, Ran L, Heaney ML, Scheinberg DA. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis. 2014;5:e1152.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Jeong SM, Lee A, Lee J, Haigis MC. SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. J Biol Chem. 2014;289(7):4135–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149–59.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.

    Article  CAS  PubMed  Google Scholar 

  54. Zelenetz AD. Emerging treatment options for B-cell lymphomas. J Nat Compr Cancer Netw. 2015;13(5 Suppl):666–9.

    CAS  Google Scholar 

  55. Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Proc ASCO 2014 J Clin Oncol 32:5s, 2014 (suppl; abstr 8522).

  56. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010;17(4):400–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the intramural program of the National Cancer Institute.

Author information

Authors and Affiliations

  1. Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4N-115, 9000 Rockville Pike, Bethesda, MD, 20892, USA

    Kieron Dunleavy MD

Authors
  1. Kieron Dunleavy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kieron Dunleavy MD.

Ethics declarations

Conflict of interest

The author declares that he has no competing interests.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dunleavy, K. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL. Curr. Treat. Options in Oncol. 16, 58 (2015). https://doi.org/10.1007/s11864-015-0374-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-015-0374-0

Keywords

Search

Navigation